A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Stopped The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years.
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
- DRUG: Rituximab
- DRUG: Obinutuzumab
- DRUG: Cyclophosphamide
- DRUG: Doxorubicin
- DRUG: Vincristine
- DRUG: Prednisone
Sponsor
Hoffmann-La Roche
Collaborators